Spoken Alpha
CRDF
Cardiff Oncology, Inc.
Overview
Cardiff Oncology develops onvansertib, an oral PLK1 inhibitor drug candidate being tested in clinical trials for various cancers including metastatic colorectal cancer, pancreatic cancer, lung cancer, breast cancer, and leukemia, primarily in combination with standard chemotherapy treatments.
Cardiff Oncology, Inc is a Healthcare company operating in Biotechnology with a $88.9M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
5 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $-0.16—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $-0.16 | — | — | — | — | EODHD |
Source: EODHD. CRDF reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks CRDF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $2.62 | $2.30 | +14.1% | +5.7% | +5.5% |
| Q4 FY2024 | $2.62 | $2.36 | +10.9% | +1.9% | +3.6% |
| Q3 FY2024 | $2.53 | $2.13 | +18.6% | +1.6% | +4.4% |
| Q2 FY2024 | $2.47 | $2.35 | +5.0% | +1.9% | 0.0% |
| Q1 FY2023 | $2.77 | $2.36 | +17.5% | +8.4% | +6.2% |
| Q4 FY2023 | $2.61 | $2.27 | +14.8% | +5.7% | +5.2% |
| Q3 FY2023 | $2.62 | $2.45 | +6.9% | -0.8% | +1.4% |
| Q2 FY2023 | $2.73 | $2.31 | +18.3% | +6.5% | +6.9% |
| Q1 FY2022 | $2.80 | $2.39 | +17.1% | -0.8% | +0.8% |
| Q4 FY2022 | $2.54 | $2.39 | +6.3% | 0.0% | +0.6% |
Guidance change history
Sample- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Mani MohindruCEO3 mono recorded callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2024
- Joshua B MuntnerCFO2 mono recorded callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2024
- Ajay AggarwalCOO2 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2024
- Brigitte Ute LindsayChief Accounting Officer5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last call held guidance Q1 FY2024
- Roger SidhuChief Medical Officer1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • guidance suspended Q1 FY2024
- Tod SmealChief Scientific Officer2 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last guidance cut Q2 FY2024
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CRDF.
$ curl https://api.spokenalpha.com/v1/companies/CRDFFAQ
Frequently asked about CRDF
Where can I find Cardiff Oncology, Inc.'s (CRDF) earnings call transcripts?
Spoken Alpha indexes CRDF's earnings call transcripts at https://spokenalpha.com/companies/CRDF. Each call links to attributed speakers and parsed analyst Q&A.
When was Cardiff Oncology, Inc.'s most recent earnings call?
Cardiff Oncology, Inc. (CRDF) held its most recent earnings call on 2025-02-27, covering fiscal Q4 2024.
What sector is CRDF in?
Cardiff Oncology, Inc. (CRDF) operates in the Healthcare sector (Biotechnology industry).